Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 8, 2011, Pages 3812-3820

  Berke, Jan Martin ^a   Vijgen, Leen ^a   Lachau Durand, Sophie ^a   Powdrill, Megan H ^b   Rawe, Svea ^b   Sjuvarsson, Elena ^c   Eriksson, Staffan ^c   Götte, Matthias ^b   Fransen, Els ^a   Dehertogh, Pascale ^a   Van Den Eynde, Christel ^a   Leclercq, Laurent ^d   Jonckers, Tim H M ^a   Raboisson, Pierre ^a   Nilsson, Magnus ^e   Samuelsson, Bertil ^e   Rosenquist, Åsa ^e   Fanning, Gregory C ^a   Lin, Tse I ^a  

^a Tibotec Virco Virology BVBA   (Belgium)

^b MCGILL UNIVERSITY   (Canada)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e MEDIVIR AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' SPIROCYCLOPROPYLCYTIDINE; ANTIVIRUS AGENT; DRUG METABOLITE; HEPATITIS C VIRUS NS5B POLYMERASE; MESSENGER RNA; MITOCHONDRIAL DNA; RNA DIRECTED RNA POLYMERASE; RNA DIRECTED RNA POLYMERASE INHIBITOR; TMC 647078; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS RNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; PRIORITY JOURNAL; RNA ANALYSIS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; CYTIDINE; DEOXYCYTIDINE KINASE; HEPACIVIRUS; HUMANS; MITOCHONDRIA; PHENOTYPE; PHOSPHORYLATION; PROTEASE INHIBITORS; RNA, VIRAL; SPIRO COMPOUNDS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 79960290446     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00214-11     Document Type: Article

References (40)

1. Ali, S., et al. 2008. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob. Agents Chemother. 52:4356-4369.
2. Beaulieu, P. L. 2009. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Expert Opin. Ther. Pat. 19:145-164.
3. Behrens, S.-E., L. Tomei, and R. De Francesco. 1996. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15:12-22. (Pubitemid 26020384)
4. Blight, K. J., J. A. McKeating, J. Marcotrigiano, and C. M. Rice. 2003. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J. Virol. 77:3181-3190.
5. Blight, K. J., J. A. McKeating, and C. M. Rice. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76:13001-13014.
6. De Clercq, E. 2007. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6:1001-1018.
7. Deuffic-Burban, S., T. Poynard, M. S. Sulkowski, and J. B. Wong. 2007. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J. Viral Hepat. 14:107-115.
8. Deval, J., M. H. Powdrill, C. M. D'Abramo, L. Cellai, and M. Gotte. 2007. Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 51:2920-2928.
9. Eriksson, S., B. Munch-Petersen, K. Johansson, and H. Eklund. 2002. Structure and function of cellular deoxyribonucleoside kinases. Cell. Mol. Life Sci. 59:1327-1346.
10. Ghobrial, R. M., et al. 2001. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann. Surg. 234:384-393.
11. Global Burden of Hepatitis C Working Group. 2004. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol. 44:20-29.
12. Gong, E., T. Ivens, C. Van den Eynde, S. Hallenberger, and K. Hertogs. 2008. Development of robust antiviral assays for profiling compounds against a panel of positive-strand RNA viruses using ATP/luminescence readout. J. Virol. Methods 151:121-125.
13. Jochmans, D., et al. 2006. Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action. J. Virol. 80: 12283-12292. (Pubitemid 44904378)
14. Jonckers, T. H., et al. 2010. 2′-Deoxy-2′- spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase. J. Med. Chem. 53:8150-8160.
15. Klumpp, K., et al. 2008. 2′-Deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alphahydroxyl groups. J. Biol. Chem. 283:2167-2175.
16. Koch, U., and F. Narjes. 2007. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr. Top. Med. Chem. 7:1302-1329.
17. Koev, G., and W. Kati. 2008. The emerging field of HCV drug resistance. Expert Opin. Invest. Drugs 17:303-319.
18. Korba, B. E., and J. L. Gerin. 1992. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res. 19:55-70.
19. Legrand-Abravanel, F., F. Nicot, and J. Izopet. 2010. New NS5B polymerase inhibitors for hepatitis C. Expert Opin. Invest. Drugs 19:963-975.
20. Lenz, O., et al. 2010. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob. Agents Chemother. 54: 1878-1887.
21. Le Pogam, S., et al. 2006. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351:349-359.
22. Le Pogam, S., et al. 2010. RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J. Infect. Dis. 202:1510-1519.
23. Lin, T.-I., et al. 2009. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob. Agents Chemother. 53:1377-1385.
24. Lohmann, V., S. Hoffmann, U. Herian, F. Penin, and R. Bartenschlager. 2003. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 77:3007-3019. (Pubitemid 36228086)
25. Lohmann, V., F. Korner, U. Herian, and R. Bartenschlager. 1997. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J. Virol. 71:8416-8428. (Pubitemid 27446422)
26. Lohmann, V., et al. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113. (Pubitemid 29307577)
27. Ma, H., et al. 2007. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2′-Deoxy-2′-fluoro- 2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J. Biol. Chem. 282:29812-29820.
28. Manns, M. P., et al. 2007. The way forward in HCV treatment - finding the right path. Nat. Rev. Drug Discov. 6:991-1000.
29. Micallef, J. M., J. M. Kaldor, and G. J. Dore. 2006. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepat. 13:34-41.
30. Migliaccio, G., et al. 2003. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278:49164-49170.
31. Murakami, E., et al. 2007. Mechanism of activation of beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob. Agents Chemother. 51:503-509.
32. Nyanguile, O., et al. 2010. 1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus. J. Virol. 84:2923-2934.
33. Olsen, D. B., et al. 2004. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob. Agents Chemother. 48:3944-3953.
34. Pauwels, F., et al. 2007. Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors. J. Virol. 81:6909-6919. (Pubitemid 46986627)
35. Raboisson, P., et al. 2008. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg. Med. Chem. Lett. 18:4853-4858.
36. Simmonds, P. 2004. Genetic diversity and evolution of hepatitis C virus - 15 years on. J. Gen. Virol. 85:3173-3188.
37. Strader, D. B., T. Wright, D. L. Thomas, L. B. Seeff, and the American Association for the Study of Liver Diseases. 2004. Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171.
38. Van Rompay, A. R., A. Norda, K. Linden, M. Johansson, and A. Karlsson. 2001. Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol. Pharmacol. 59:1181-1186.
39. Wang, L., and S. Eriksson. 2000. Cloning and characterization of full-length mouse thymidine kinase 2: the N-terminal sequence directs import of the precursor protein into mitochondria. Biochem. J. 351(Pt. 2):469-476.
40. Wang, L., A. Karlsson, E. S. Arner, and S. Eriksson. 1993. Substrate specificity of mitochondrial 2′-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine. J. Biol. Chem. 268:22847-22852.